Biopharma Stocks Surge as Tech Wreck Drives Investors to Lilly, Gilead, and J&J

While tech stocks tumble, shares of major drugmakers are hitting record highs, with Eli Lilly, Gilead Sciences, and Johnson & Johnson emerging as standout winners. The shift reflects a broader rotation by investors seeking stability and reliable growth amid market volatility. These biopharma giants offer strong pipelines, steady cash flows, and defensive characteristics that appeal in uncertain times. Lilly’s leadership in diabetes and obesity treatments, Gilead’s expanding oncology and HIV portfolio, and J&J’s diversified healthcare business are key drivers. The trend underscores how healthcare is becoming a safe haven as high-flying tech valuations come under pressure. With interest rates and economic concerns lingering, more capital may flow into drugmakers known for resilience and innovation.